OncoZenge can confirm that comprehensive analyses show that the adjusted formulation of BupiZenge is clean. Stability studies will now continue as planned. The company asserting that a clean and stable product formulation has great commercial value for potential licensees and strategic partners, as a proven, working product is the basis for continued clinical study and an eventual market approval.

As announced in the financial report for the third quarter, the company has for some time analyzed the cause of the previously announced impurity in the lozenge formulation of BupiZ Challenge. The root cause has been identified and several options for a minor adjustment in the formulation required to prevent the impurity from occurring have been analyzed. Based on these analyses, the company's new management team decided to resume work on the formulation and several compatibility studies have since been carried out.

all three variants of an adjusted formulation have shown positive stability data. No impurities have been detected, fully in accordance with the expectations from the prior analysis. Confidence is further strengthened by the fact that the previous formulation has proven to be clean after four months of stability studies in packaging different than the one used in earlier studies.

Taken together, these results from comprehensive analyses clearly delineate the root cause and causality of the previously announced impurity. stability studies will now continue according to plan, and the company will update the market as additional data becomes available.